Comparative Oral Bioavailability Study of MT-1303

Phase 1

Completed

• Conditions: Relapsing-remitting Multiple Sclerosis
• Interventions: Drug: MT-1303-FormB; Drug: MT-1303-FormA

• Registration Number: NCT02310048
• Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Brief Summary

The purpose of this study is to assess the comparative oral bioavailability of a Formulation B versus the Formulation A of MT-1303.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-11
• Study First Submitted: 2014-11-14
• Study First Submitted QC: 2014-12-03
• Study First Posted: 2014-12-05
• Status Verified: 2015-03
• Primary Completion: 2015-03
• Study Completion: 2015-03
• Last Update Submitted: 2015-03-13
• Last Update Posted: 2015-03-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 34

Inclusion Criteria

• Caucasian males aged 18 to 55 years at Screening.
• Healthy and free from clinically significant illness or disease as determined by medical history, physical examination, laboratory, and other tests at Screening and Day -1.
• A body weight of ≥60 kilograms (kg) and BMI ranging from 18 to 30 kg/m2 at Screening or Day -1.

Read More

Exclusion Criteria

• Presence or history of severe adverse reaction or allergy to any medicinal product or relevant excipient that is of clinical significance.
• Participated in more than three clinical studies of a new chemical entity in the previous year or participated in a clinical study of any IMP within 12 weeks or five half-lives of the IMP before the administration of the IMP in this clinical study.
• Clinically relevant abnormal medical history, physical findings, or laboratory values at Screening or Day -1 that could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator.
• Previous medical history of tuberculosis or in the opinion of the Investigator a recurrent medical history of cold sores, pharyngitis, urinary tract infection, diarrhoea/dysentery, chest infections, or fungal infection.
• Subjects who have received any prescribed systemic or topical medication within 14 days prior to administration of the IMP(Day 1) unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety. Slow release medicinal formulations considered to still be active within 14 days prior to the first dose administration will also be excluded unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MT-1303-FormB	MT-1303-FormB	MT-1303, Capsule Formulation B
MT-1303-FormA	MT-1303-FormA	MT-1303, Capsule Formulation A

Primary Outcome Measures

Name	Time	Method
Area under the concentration-time curve(AUC) .	up to 6 weeks

Secondary Outcome Measures

Name	Time	Method
Half-life(t1/2.) of MT-1303	up to 6 weeks
Time to reach peak concentration (Tmax) of MT-1303	up to 6 weeks
Peak drug concentration (Cmax) of MT-1303	up to 6 weeks

Trial Locations

Locations (1)

Investigational site; 🇬🇧 Leeds, United Kingdom